Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Compare the Safety and Performance of MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions

NCT05417893 is registered in ClinicalTrials.gov with Meril Life Sciences Pvt. Ltd. as lead sponsor.

NCT NCT05417893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05417893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Compare the Safety and Performance of MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions
Lead sponsor
Meril Life Sciences Pvt. Ltd.
Phase
Not applicable
Overall status
Withdrawn
Start date
October 15, 2022
Completion date
September 23, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease